Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes 13 RNAi-Related Patent Applications

Premium
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20060293272
 
Filed: Aug. 4, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20060293271
 
Filed: Aug. 4, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: Antisense Modulation of Superoxide Dismutase 1, Soluble Expression
 
Number: 20060293269
 
Filed: June 7, 2006
 
Lead Inventor: Frank Bennett, Isis Pharmaceuticals
 
The patent application, its abstract states, covers “antisense compounds, compositions and methods … for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided” in the application, as well.
 

 
Title: Dual Functional Oligonucleotides for Use as Anti-Viral Agents
 
Number: 20060293267
 
Filed: April 13, 2006
 
Lead Inventor: Phillip Zamore, University of Massachusetts
 
The invention, the patent application’s abstract states, “is based, in part, on the discovery that endogenous mRNAs, such as viral miRNAs, can be recruited for translational repression of target mRNAs, such as viral target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means of treating viral infections, of treating diseases, or disorders caused by viral infections, or for preventing viral propagation. The RNA-silencing agents of the … invention have an mRNA targeting moiety, a linking moiety, and a viral miRNA recruiting moiety.”
 

 
Title: Inhibition of Gene Expression Using RNA Interfering Agents
 
Number: 20060293262
 
Filed: Oct. 29, 2003 OCT Filed: Oct. 29, 2003
 
Lead Inventor: Judy Lieberman, Harvard Medical School
 
The invention, according to the patent application’s abstract, “is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the … invention pertains to methods of modulating cellular gene expression or protein activity, e.g., CCR5, gene expression or protein activity and/or gene expression or protein activity of a gene or sequence of an infectious agent, in order to treat or prevent infectious diseases or disorders, HIV infection, AIDS, or an AIDS-related disease or disorder. In one embodiment the combination of an RNA interfering agent targeting a cellular gene in combination with an RNA interfering agent targeting a gene or sequence of an infectious agent results in prolonged prevention of infection by an infectious agent,” the abstract adds. “The … invention is based on the identification of novel RNA interference agents, e.g., siRNA molecules, which target cellular genes, e.g., chemokine receptors, e.g., the CCR5 gene, and result in inhibition of target gene expression on target gene expressing cells, thereby inhibiting entry of infectious agents, e,g., HIV infection into target cells, prevention infection, and/or suppressing replication in established infection.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20060292691
 
Filed: Aug. 11, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: Methods for Determining Specificity of RNA Silencing and for Genetic Analysis of the Silenced Gene or Protein
 
Number: 20060287272
 
Filed: June 14, 2006
 
Lead Inventor: Daniel Klessig, Cornell University
 
According to the patent application’s abstract, the invention comprises “methods and kits for determining the specificity of siRNAs for their targets. Also provided [under the invention] is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene of interest. Finally, [the application covers] a method for treating genetic disorders associated with production of mutated proteins.”
 

 
Title: Short Interfering Nucleic Acid Hybrids and Methods Thereof
 
Number: 20060287269
 
Filed: May 15, 2006
 
Lead Inventor: Allen Christian, Lawrence Livermore National Laboratory
 
Disclosed in the patent application, according to its abstract, “are siHybrids used for gene silencing. An siHybrid is a short double-stranded molecule comprised of one strand of DNA and one strand of RNA, annealed together, with a 2-base overhang at each 3' end. In addition to DNA and RNA, it may contain PNA or other nucleic acid analogs,” the abstract notes. “siHybrids can silence a gene with greater magnitude and duration than siRNA … [and] are ideal candidates for pharmaceutical and therapeutic agents for treating diseases caused by an over-expressed gene or a cancerous gene. siHybrids can be used as antivirus agents, fungicides, herbicides or pesticides. An appropriate siHybrid can be designed to silence any gene in any eukaryotic cell or organism.”
 

 
Title: RNA Interference-Mediated Inhibition of Respiratory Syncytial Virus Expression Using Short Interfering Nucleic Acid
 
Number: 20060287267
 
Filed: March 31, 2006
 
Lead Inventor: Narendra Vaish, Sirna Therapeutics (Merck)
 
“This invention relates to compounds, compositions, and methods useful for modulating respiratory syncytial virus gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RSV gene expression and/or activity by RNA interference using small nucleic acid molecules. … The application also relates to methods of treating diseases and conditions associated with RSV gene expression, such as RSV infection, respiratory failure, bronchiolitis and pneumonia, as well as providing dosing regimens and treatment protocols.”
 

 
Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
 
Number: 20060287266
 
Filed: Feb. 21, 2006
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.”
 

 
Title: RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof
 
Number: 20060287264
 
Filed: Nov. 23, 2005
 
Lead Inventor: Philip Hadwiger, Alnylam Europe (Alnylam Pharmaceuticals)
 
“The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides,” the patent application’s abstract states.
 

 
Title: Oligonucleotides Comprising a Non-Phosphate Backbone Linkage
 
Number: 20060287260
 
Filed: June 29, 2005
 
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
 
“One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3'-position,” according to the patent application’s abstract. “In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety,” the abstract states.
 
“Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages,” the abstract notes. “In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.”
 

 
Title: Compositions and Methods for Combined Therapy of Disease
 
Number: 20060287259
 
Filed: Dec. 23, 2004
 
Lead Inventor: Sam Reich, University of Pennsylvania (Acuity Pharmaceuticals)
 
“A desired physiological state can be induced by altering the amount of gene products in target cells of a subject,” the patent application’s abstract states. “The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to increase expression from at least one second gene. The reduced expression of the first gene and the increased expression from the second gene in the target cells induces the desired physiological state in the subject. By altering target cell gene expression in this way, conditions such as angiogenesis or tumor growth and metastasis can be inhibited.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.